Skip to main content
Erschienen in: Journal of Behavioral Medicine 5/2011

01.10.2011

Exacerbation history is associated with medication and appointment adherence in MS

verfasst von: Laura M. Hancock, Jared M. Bruce, Sharon G. Lynch

Erschienen in: Journal of Behavioral Medicine | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Disease-modifying treatments are designed to prevent exacerbations in multiple sclerosis (MS). To date, few studies have examined the relationship between disease activity and treatment adherence in MS. The primary aim of this study was to examine the association between disease activity (e.g., annualized relapse rates), medication adherence, and appointment adherence in relapsing-remitting MS. Retrospective exacerbation and appointment data were collected and used to predict prospective medication adherence. Results indicated that patients with higher annualized relapse rates missed fewer doses of medication and were less likely to miss appointments. Conversely, patients with relatively stable disease were more likely to demonstrate poor medication adherence and poor appointment adherence. Patients who missed more appointments also missed more doses of their disease modifying medication. Future studies may wish to examine clinical methods designed to improve immunotherapy adherence among patients who are in relatively symptom-free stages of relapsing-remitting MS.
Literatur
Zurück zum Zitat Anderson, D. W., Ellenberg, J. H., Leventhal, C. M., Reingold, S. C., Rodriguez, M., & Silberberg, D. H. (1992). Revised estimate of the prevalence of multiple sclerosis in the United States. Annals of Neurology, 31, 333–336. doi:10.1002/ana.410310317.PubMedCrossRef Anderson, D. W., Ellenberg, J. H., Leventhal, C. M., Reingold, S. C., Rodriguez, M., & Silberberg, D. H. (1992). Revised estimate of the prevalence of multiple sclerosis in the United States. Annals of Neurology, 31, 333–336. doi:10.​1002/​ana.​410310317.PubMedCrossRef
Zurück zum Zitat Arnett, P. A., Barwick, F. H., & Beeney, J. E. (2008). Depression in multiple sclerosis: Review and theoretical proposal. Journal of the International Neuropsychological Society, 14, 691–724.PubMed Arnett, P. A., Barwick, F. H., & Beeney, J. E. (2008). Depression in multiple sclerosis: Review and theoretical proposal. Journal of the International Neuropsychological Society, 14, 691–724.PubMed
Zurück zum Zitat Benedict, R. H. B., Wahlig, E., Bakshi, R., Fishman, I., Munschauer, F., Zivadinov, R., et al. (2005). Predicting quality of life in multiple sclerosis: Accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. Journal of Neurological Sciences, 231, 29–34.CrossRef Benedict, R. H. B., Wahlig, E., Bakshi, R., Fishman, I., Munschauer, F., Zivadinov, R., et al. (2005). Predicting quality of life in multiple sclerosis: Accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. Journal of Neurological Sciences, 231, 29–34.CrossRef
Zurück zum Zitat Bruce, J. M., & Arnett, P. (2009). Clinical correlates of generalized worry in multiple sclerosis. Journal of Clinical and Experimental Neuropsychology, 31, 698–705.PubMedCrossRef Bruce, J. M., & Arnett, P. (2009). Clinical correlates of generalized worry in multiple sclerosis. Journal of Clinical and Experimental Neuropsychology, 31, 698–705.PubMedCrossRef
Zurück zum Zitat Bruce, J. M., Bruce, A. S., & Arnett, P. A. (2007a). Mild visual acuity disturbances are associated with performance on tests of complex visual attention in MS. Journal of the International Neuropsychological Society, 13, 544–548.PubMedCrossRef Bruce, J. M., Bruce, A. S., & Arnett, P. A. (2007a). Mild visual acuity disturbances are associated with performance on tests of complex visual attention in MS. Journal of the International Neuropsychological Society, 13, 544–548.PubMedCrossRef
Zurück zum Zitat Bruce, J. M., Hancock, L., Arnett, P., & Lynch, S. (2010a). Treatment adherence in multiple sclerosis: Association with emotional status, personality, and cognition. Journal of Behavioral Medicine, 33, 219–227.PubMedCrossRef Bruce, J. M., Hancock, L., Arnett, P., & Lynch, S. (2010a). Treatment adherence in multiple sclerosis: Association with emotional status, personality, and cognition. Journal of Behavioral Medicine, 33, 219–227.PubMedCrossRef
Zurück zum Zitat Bruce, J. M., Hancock, L., & Lynch, S. (2010b). Objective adherence monitoring in MS: Initial validation and association with self-report. Multiple Sclerosis, 16, 112–120.PubMedCrossRef Bruce, J. M., Hancock, L., & Lynch, S. (2010b). Objective adherence monitoring in MS: Initial validation and association with self-report. Multiple Sclerosis, 16, 112–120.PubMedCrossRef
Zurück zum Zitat Bruce, J. M., Polen, D., & Arnett, P. A. (2007b). Pain and affective memory biases interact to predict depressive symptoms in multiple sclerosis. Multiple Sclerosis, 13, 58–66.PubMedCrossRef Bruce, J. M., Polen, D., & Arnett, P. A. (2007b). Pain and affective memory biases interact to predict depressive symptoms in multiple sclerosis. Multiple Sclerosis, 13, 58–66.PubMedCrossRef
Zurück zum Zitat Clerico, M., Barbero, P., Contessa, G., Ferrero, C., & Durelli, L. (2007). Adherence to interferon-beta treatment and results of therapy switching. Journal of the Neurological Sciences, 259, 104–108.PubMedCrossRef Clerico, M., Barbero, P., Contessa, G., Ferrero, C., & Durelli, L. (2007). Adherence to interferon-beta treatment and results of therapy switching. Journal of the Neurological Sciences, 259, 104–108.PubMedCrossRef
Zurück zum Zitat Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, O., et al. (2001). Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomized study. Lancet, 357, 1576–1582.PubMedCrossRef Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, O., et al. (2001). Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomized study. Lancet, 357, 1576–1582.PubMedCrossRef
Zurück zum Zitat Coyle, P. K. (2008). Early treatment of multiple sclerosis to prevent neurologic damage. Neurology, 71, S3–S7.PubMedCrossRef Coyle, P. K. (2008). Early treatment of multiple sclerosis to prevent neurologic damage. Neurology, 71, S3–S7.PubMedCrossRef
Zurück zum Zitat Cramer, J. A. (1998). Consequences of intermittent treatment for hypertension: The case for medication compliance and persistence. The American Journal of Managed Care, 4, 1563–1568.PubMed Cramer, J. A. (1998). Consequences of intermittent treatment for hypertension: The case for medication compliance and persistence. The American Journal of Managed Care, 4, 1563–1568.PubMed
Zurück zum Zitat Cree, B. A. C., Khan, O., Bourdette, D., Goodin, D. S., Cohen, J. A., Marrie, R. A., et al. (2004). Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology, 63, 2039–2045.PubMed Cree, B. A. C., Khan, O., Bourdette, D., Goodin, D. S., Cohen, J. A., Marrie, R. A., et al. (2004). Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology, 63, 2039–2045.PubMed
Zurück zum Zitat Davis, M. C., Tucker, C. M., & Fennell, R. S. (1996). Family behavior, adaptation, and treatment adherence of pediatric nephrology patients. Pediatric Nephrology, 10, 160–166.PubMed Davis, M. C., Tucker, C. M., & Fennell, R. S. (1996). Family behavior, adaptation, and treatment adherence of pediatric nephrology patients. Pediatric Nephrology, 10, 160–166.PubMed
Zurück zum Zitat Dietz, E., Clum, G. A., Chung, S. E., Leonard, L., Murphy, D. A., Perez, L. V., et al. (2010). Adherence to scheduled appointments among HIV-infected female youth in five U.S. cities. Journal of Adolescent Health, 46, 278–283.PubMedCrossRef Dietz, E., Clum, G. A., Chung, S. E., Leonard, L., Murphy, D. A., Perez, L. V., et al. (2010). Adherence to scheduled appointments among HIV-infected female youth in five U.S. cities. Journal of Adolescent Health, 46, 278–283.PubMedCrossRef
Zurück zum Zitat Duff, A., & Latchford, G. J. (2010). Motivational interviewing for adherence problems in cystic fibrosis. Pediatric Pulmonology, 45, 211–220.PubMed Duff, A., & Latchford, G. J. (2010). Motivational interviewing for adherence problems in cystic fibrosis. Pediatric Pulmonology, 45, 211–220.PubMed
Zurück zum Zitat Finney, J., Lemanek, K. L., Brophy, C. J., & Cataldo, M. F. (1990). Pediatric appointment keeping: Improving adherence in a primary care allergy clinic. Journal of Pediatric Psychology, 15, 571–579.PubMedCrossRef Finney, J., Lemanek, K. L., Brophy, C. J., & Cataldo, M. F. (1990). Pediatric appointment keeping: Improving adherence in a primary care allergy clinic. Journal of Pediatric Psychology, 15, 571–579.PubMedCrossRef
Zurück zum Zitat Fraser, C., Hadjimichael, O., & Vollmer, T. (2003). Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis. Journal of Neuroscience Nursing, 35, 163–174.PubMedCrossRef Fraser, C., Hadjimichael, O., & Vollmer, T. (2003). Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis. Journal of Neuroscience Nursing, 35, 163–174.PubMedCrossRef
Zurück zum Zitat Goodin, D. S. (2008). Disease-modifying therapy in multiple sclerosis: Update and clinical implications. Neurology, 71, 8–13.CrossRef Goodin, D. S. (2008). Disease-modifying therapy in multiple sclerosis: Update and clinical implications. Neurology, 71, 8–13.CrossRef
Zurück zum Zitat Goodin, D. S., Frohman, E. M., Garmany, G. P., Jr., Halper, J., Likosky, W. H., Lublin, F. D., et al. (2002). Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for clinical practice guidelines. Neurology, 58, 169–178.PubMed Goodin, D. S., Frohman, E. M., Garmany, G. P., Jr., Halper, J., Likosky, W. H., Lublin, F. D., et al. (2002). Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for clinical practice guidelines. Neurology, 58, 169–178.PubMed
Zurück zum Zitat Hobart, J., Freeman, J., & Thompson, A. (2000). Kurtzke scales revisited: The application of psychometric methods to clinical intuition. Brain, 123, 1027–1040.PubMedCrossRef Hobart, J., Freeman, J., & Thompson, A. (2000). Kurtzke scales revisited: The application of psychometric methods to clinical intuition. Brain, 123, 1027–1040.PubMedCrossRef
Zurück zum Zitat Interian, A., Martinez, I., Rios, L. I., Krejci, J., & Guarnaccia, P. J. (2010). Adaptation of a motivational interviewing intervention to improve antidepressant adherence among Latinos. Cultural Diversity and Ethnic Minority Psychology, 16, 215–225. doi:10.1037/a0016072.PubMedCrossRef Interian, A., Martinez, I., Rios, L. I., Krejci, J., & Guarnaccia, P. J. (2010). Adaptation of a motivational interviewing intervention to improve antidepressant adherence among Latinos. Cultural Diversity and Ethnic Minority Psychology, 16, 215–225. doi:10.​1037/​a0016072.PubMedCrossRef
Zurück zum Zitat Jacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., et al. (2001). Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. American Journal of Opthamology, 131, 898–904. Jacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., et al. (2001). Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. American Journal of Opthamology, 131, 898–904.
Zurück zum Zitat Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., et al. (1996). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Annals of Neurology, 39, 285–294.PubMedCrossRef Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., et al. (1996). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Annals of Neurology, 39, 285–294.PubMedCrossRef
Zurück zum Zitat Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., et al. (1995). Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology, 45, 1268–1276.PubMed Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., et al. (1995). Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology, 45, 1268–1276.PubMed
Zurück zum Zitat Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P., Miller, D. H., et al. (2006). Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology, 67, 1242–1249.PubMedCrossRef Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P., Miller, D. H., et al. (2006). Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology, 67, 1242–1249.PubMedCrossRef
Zurück zum Zitat Karter, A. J., Parker, M. M., Moffet, H. H., Ahmed, A., Ferrara, A., Liu, J. Y., et al. (2004). Missed appointments and poor glycemic control: An opportunity to identify high-risk diabetic patients. Medical Care, 42, 110–115.PubMedCrossRef Karter, A. J., Parker, M. M., Moffet, H. H., Ahmed, A., Ferrara, A., Liu, J. Y., et al. (2004). Missed appointments and poor glycemic control: An opportunity to identify high-risk diabetic patients. Medical Care, 42, 110–115.PubMedCrossRef
Zurück zum Zitat Kieseier, B. C., Wiendl, H., Leussink, V. I., & Stuve, O. (2008). Immunomodulatory treatment strategies in multiple sclerosis. Journal of Neurology, 255, 15–21.PubMedCrossRef Kieseier, B. C., Wiendl, H., Leussink, V. I., & Stuve, O. (2008). Immunomodulatory treatment strategies in multiple sclerosis. Journal of Neurology, 255, 15–21.PubMedCrossRef
Zurück zum Zitat Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology, 33, 1444–1452.PubMed Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology, 33, 1444–1452.PubMed
Zurück zum Zitat Lublin, F. D., & Reingold, S. C. (1996). Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology, 46, 907–911.PubMed Lublin, F. D., & Reingold, S. C. (1996). Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology, 46, 907–911.PubMed
Zurück zum Zitat Maxwell, S., Maljanian, R., Horowitz, S., Pianka, M. A., Cabrera, Y., & Greene, J. (2001). Effectiveness of reminder systems on appointment adherence rates. Journal of Health Care for the Poor and Underserved, 12, 504–514.PubMed Maxwell, S., Maljanian, R., Horowitz, S., Pianka, M. A., Cabrera, Y., & Greene, J. (2001). Effectiveness of reminder systems on appointment adherence rates. Journal of Health Care for the Poor and Underserved, 12, 504–514.PubMed
Zurück zum Zitat McClure, J. B., Catz, S. L., & Brantley, P. J. (1999). Early appointment adherence among persons living with HIV. AIDS and Behavior, 3, 157–165.CrossRef McClure, J. B., Catz, S. L., & Brantley, P. J. (1999). Early appointment adherence among persons living with HIV. AIDS and Behavior, 3, 157–165.CrossRef
Zurück zum Zitat Medley, A. R., & Powell, T. (2010). Motivational interviewing to promote self-awareness and engagement in rehabilitation following acquired brain injury: A conceptual review. Neuropsychological Rehabilitation, Epub ahead of print. Medley, A. R., & Powell, T. (2010). Motivational interviewing to promote self-awareness and engagement in rehabilitation following acquired brain injury: A conceptual review. Neuropsychological Rehabilitation, Epub ahead of print.
Zurück zum Zitat Mitsonis, C. I., Zervas, I. M., Mitropoulos, P. A., Dimopoulos, N. P., Soldatos, C. R., & Potagas, C. M. (2008). The impact of stressful life events on risk of relapse in women with multiple sclerosis: A prospective study. European Psychiatry, 23, 497–504. doi:10.1016/j.eurpsy.2008.06.003.PubMedCrossRef Mitsonis, C. I., Zervas, I. M., Mitropoulos, P. A., Dimopoulos, N. P., Soldatos, C. R., & Potagas, C. M. (2008). The impact of stressful life events on risk of relapse in women with multiple sclerosis: A prospective study. European Psychiatry, 23, 497–504. doi:10.​1016/​j.​eurpsy.​2008.​06.​003.PubMedCrossRef
Zurück zum Zitat Mohr, D. C., Boudewyn, A. C., Likosky, W., Levine, E., & Goodkin, D. E. (2001). Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Annals of Behavioral Medicine, 23, 125–132.PubMedCrossRef Mohr, D. C., Boudewyn, A. C., Likosky, W., Levine, E., & Goodkin, D. E. (2001). Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Annals of Behavioral Medicine, 23, 125–132.PubMedCrossRef
Zurück zum Zitat Mohr, D. C., Goodkin, D. E., Likosky, W., Gatto, N., Baumann, K. A., & Rudick, R. A. (1997). Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Archives of Neurology, 54, 531–533.PubMed Mohr, D. C., Goodkin, D. E., Likosky, W., Gatto, N., Baumann, K. A., & Rudick, R. A. (1997). Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Archives of Neurology, 54, 531–533.PubMed
Zurück zum Zitat Mollon, B., Holbrook, A. M., Keshavjee, K., Troyan, S., Gaebel, K., & Thabane, L. (2008). Automated telephone reminder messages can assist electronic diabetes care. Journal of Telemedicine and Telecare, 14, 32–36. doi:10.1258/jtt.2007.070702.PubMedCrossRef Mollon, B., Holbrook, A. M., Keshavjee, K., Troyan, S., Gaebel, K., & Thabane, L. (2008). Automated telephone reminder messages can assist electronic diabetes care. Journal of Telemedicine and Telecare, 14, 32–36. doi:10.​1258/​jtt.​2007.​070702.PubMedCrossRef
Zurück zum Zitat Moore, C. G., Wilson-Witherspoon, P., & Probst, J. C. (2001). Time and money: Effects of no-shows at a family practice residency clinic. Family Medicine, 33, 522–527.PubMed Moore, C. G., Wilson-Witherspoon, P., & Probst, J. C. (2001). Time and money: Effects of no-shows at a family practice residency clinic. Family Medicine, 33, 522–527.PubMed
Zurück zum Zitat Outlaw, A., Naar-King, S., Green-Jones, M., Wright, K., Condon, K., Sherry, L., & Janisse, H. (2010). Brief report: Predictors of optimal HIV appointment adherence in minority youth: A prospective study. Journal of Pediatric Psychology, 35, 1011–1015. doi:10.1093/jpepsy/jsq002. Outlaw, A., Naar-King, S., Green-Jones, M., Wright, K., Condon, K., Sherry, L., & Janisse, H. (2010). Brief report: Predictors of optimal HIV appointment adherence in minority youth: A prospective study. Journal of Pediatric Psychology, 35, 1011–1015. doi:10.​1093/​jpepsy/​jsq002.
Zurück zum Zitat Patti, F. (2009). Optimizing the benefit of multiple sclerosis therapy: The importance of treatment adherence. Patient Preference and Adherence, 4, 1–9. Patti, F. (2009). Optimizing the benefit of multiple sclerosis therapy: The importance of treatment adherence. Patient Preference and Adherence, 4, 1–9.
Zurück zum Zitat Pesata, V., Palliga, G., & Webb, A. A. (1999). A descriptive study of missed appointments: Families’ perceptions of barriers to care. Journal of Pediatric Health Care, 13, 178–182.PubMedCrossRef Pesata, V., Palliga, G., & Webb, A. A. (1999). A descriptive study of missed appointments: Families’ perceptions of barriers to care. Journal of Pediatric Health Care, 13, 178–182.PubMedCrossRef
Zurück zum Zitat Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H. P., Kappos, L., et al. (2005). Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Annals of Neurology, 58, 840–846.PubMedCrossRef Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H. P., Kappos, L., et al. (2005). Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Annals of Neurology, 58, 840–846.PubMedCrossRef
Zurück zum Zitat Pryse-Phillips, W., & Costello, F. (2001). The epidemiology of multiple sclerosis. New York: Marcel Dekker, Inc. Pryse-Phillips, W., & Costello, F. (2001). The epidemiology of multiple sclerosis. New York: Marcel Dekker, Inc.
Zurück zum Zitat Rio, J., Porcel, J., Tellez, N., Sanchez-Betancourt, A., Tintore, M., Arevalo, M. J., et al. (2005). Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis. Multiple Sclerosis, 11, 306–309. doi:10.1191/1352458505ms1173oa.PubMedCrossRef Rio, J., Porcel, J., Tellez, N., Sanchez-Betancourt, A., Tintore, M., Arevalo, M. J., et al. (2005). Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis. Multiple Sclerosis, 11, 306–309. doi:10.​1191/​1352458505ms1173​oa.PubMedCrossRef
Zurück zum Zitat Schumacher, G. A., Beebe, G., Kibler, R. F., Kurland, L. T., Kurtzke, J. F., McDowell, F., et al. (1965). Problems of experimental trials of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Annals of the New York Academy of Sciences, 122, 552–568.CrossRef Schumacher, G. A., Beebe, G., Kibler, R. F., Kurland, L. T., Kurtzke, J. F., McDowell, F., et al. (1965). Problems of experimental trials of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Annals of the New York Academy of Sciences, 122, 552–568.CrossRef
Zurück zum Zitat Steinberg, S. C., Faris, R. J., Chang, C. F., Chan, A., & Tankersley, M. A. (2010). Impact of adherence to inteferons in the treatment of multiple sclerosis: A non-experimental, retrospective, cohort study. Clinical Drug Investigation, 30, 89–100.PubMedCrossRef Steinberg, S. C., Faris, R. J., Chang, C. F., Chan, A., & Tankersley, M. A. (2010). Impact of adherence to inteferons in the treatment of multiple sclerosis: A non-experimental, retrospective, cohort study. Clinical Drug Investigation, 30, 89–100.PubMedCrossRef
Zurück zum Zitat The IFNB Multiple Sclerosis Study Group. (1993). Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology, 43, 655–661. The IFNB Multiple Sclerosis Study Group. (1993). Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology, 43, 655–661.
Zurück zum Zitat Uribe, A. G., Ho, K. T., Agee, B., McGwin, G., Fessler, B. J., & Bastian, H. M. (2004). Relationship between adherence to study and clinic visits in systemic lupus erythematosus patients: Data from the LUMINA cohort. Lupus, 13, 561–568. doi:10.1191/0961203304lu1061oa.PubMedCrossRef Uribe, A. G., Ho, K. T., Agee, B., McGwin, G., Fessler, B. J., & Bastian, H. M. (2004). Relationship between adherence to study and clinic visits in systemic lupus erythematosus patients: Data from the LUMINA cohort. Lupus, 13, 561–568. doi:10.​1191/​0961203304lu1061​oa.PubMedCrossRef
Zurück zum Zitat Walker, E. A., Molitch, M., Kramer, M. K., Kahn, S., Ma, Y., Edelstein, S., et al. (2006). Adherence to preventive medications: Predictors and outcomes in the Diabetes Prevention Program. Diabetes Care, 29, 1997–2002.PubMedCrossRef Walker, E. A., Molitch, M., Kramer, M. K., Kahn, S., Ma, Y., Edelstein, S., et al. (2006). Adherence to preventive medications: Predictors and outcomes in the Diabetes Prevention Program. Diabetes Care, 29, 1997–2002.PubMedCrossRef
Zurück zum Zitat Wallin, M. T., Page, W. F., & Kurtzke, J. F. (2004). Multiple sclerosis in US veterans of the Vietnam era and later military service: Race, sex, and geography. Annals of Neurology, 55, 65–71.PubMedCrossRef Wallin, M. T., Page, W. F., & Kurtzke, J. F. (2004). Multiple sclerosis in US veterans of the Vietnam era and later military service: Race, sex, and geography. Annals of Neurology, 55, 65–71.PubMedCrossRef
Zurück zum Zitat Walther, E. U., & Hohlfeld, R. (1999). Multiple sclerosis: Side effects of interferon beta therapy and their management. Neurology, 53, 1622–1627.PubMed Walther, E. U., & Hohlfeld, R. (1999). Multiple sclerosis: Side effects of interferon beta therapy and their management. Neurology, 53, 1622–1627.PubMed
Zurück zum Zitat Zivadinov, R., Zorzon, M., Tommasi, M. A., Nasuelli, D., Bernardi, M., Monti-Bragadin, L., et al. (2003). A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. Journal of the Neurological Sciences, 216, 113–118.PubMedCrossRef Zivadinov, R., Zorzon, M., Tommasi, M. A., Nasuelli, D., Bernardi, M., Monti-Bragadin, L., et al. (2003). A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. Journal of the Neurological Sciences, 216, 113–118.PubMedCrossRef
Metadaten
Titel
Exacerbation history is associated with medication and appointment adherence in MS
verfasst von
Laura M. Hancock
Jared M. Bruce
Sharon G. Lynch
Publikationsdatum
01.10.2011
Verlag
Springer US
Erschienen in
Journal of Behavioral Medicine / Ausgabe 5/2011
Print ISSN: 0160-7715
Elektronische ISSN: 1573-3521
DOI
https://doi.org/10.1007/s10865-011-9316-x

Weitere Artikel der Ausgabe 5/2011

Journal of Behavioral Medicine 5/2011 Zur Ausgabe

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.